View Post

FDA Approval Sought for F-627 for Chemotherapy-Induced Neutropenia in Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Kristi Rosa From: onclive.com A biologics license application has been submitted to the FDA for the approval of F-627 as a treatment option for patients with breast cancer who have chemotherapy-induced neutropenia. A biologics license application has been submitted to the FDA for the approval of F-627 (Ryzneuta; formerly efbemalenograstim alpha) as a treatment option for patients with breast …

View Post

New Research Indicates ProFound AI May Reduce Interval Breast Cancer Rates

In Clinical Studies News by Barbara Jacoby

Source: iCAD Inc. From: yahoo.com Retrospective analysis published in Journal of Medical Screening suggests that ProFound AI for 2D Mammography could have helped detect 48% of interval cancers and 93% of subgroups that include false-negatives and minimal sign lesions iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that ProFound® AI …

View Post

New drug could help in breast cancer fight, Scottish research finds

In Clinical Studies News by Barbara Jacoby

By: Craig Cairns From: thenational.scot A PROTEIN which helps breast cancer tumours survive could be targeted with a new type of drug that is already being tested for other cancers, research suggests The protein, known as MCL-1, helps breast cancer cells survive by hindering their natural ability to die. This process, called apoptosis, is the body’s way of getting rid …

View Post

Portage Biotech Highlights Initiation of the Invincible Trial, a Phase 2 Early Stage Breast Cancer Study from Intensity Therapeutics

In Clinical Studies News by Barbara Jacoby

Source: Newsfile Corp. From: finance.yahoo.com – The INVINCIBLE trial is a phase 2 study with a primary endpoint one month after starting treatment – Eight other phase 2 clinical data reads are expected from INT230-6 (PORT-1) over the next 24 months Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) (“Portage” or the “Company”) a clinical stage immuno-oncology company accelerating research and …

View Post

New method for scDNA sequencing provides insights into breast cancer evolution

In Clinical Studies News by Barbara Jacoby

Source: University of Texas MD Anderson Cancer Center From: news-medical.net Overcoming previous technical challenges with single-cell DNA (scDNA) sequencing, a group led by researchers at The University of Texas MD Anderson Cancer Center has developed a novel method for scDNA sequencing at single-molecule resolution. This technique revealed for the first time that triple-negative breast cancers undergo continued genetic copy number …

View Post

Greenwich LifeSciences Presents Immune Response Phase IIb Poster

In Clinical Studies News by Barbara Jacoby

From: businesswire.com Published Today at AACR 2021, Showing Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today presented a …

View Post

Breakthrough Immunotherapy Earns First Regulatory Approval for Triple Negative Breast Cancer

In Clinical Studies News by Barbara Jacoby

From: businesswire.com Immunopheresis™ therapy holds great promise for avoiding serious drawbacks of existing pharmaceuticals and improving patients’ quality of life Immunicom, Inc., a global biotechnology company pioneering novel “subtractive” immunotherapies, today announced that the Immunopheresis™ LW-02 blood-filtering column, its leading immuno-oncology product with FDA Breakthrough Device status, has received regulatory clearance (CE Mark certification) in Europe for use in adults …

View Post

Surgery Boosts Survival in De Novo Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Christina Bennett, MS From: cancertherapyadvisor.com Locoregional treatment was found to improve survival for patients with de novo stage IV breast cancer and bone-only metastasis, according to the results of a multicenter registry study reported at the 17th St. Gallen International Breast Cancer Conference 2021. BOMET MF14-01 (ClinicalTrials.gov Identifier: NCT02125630) included 505 patients with de novo stage IV breast cancer …

View Post

Intravenous Cetirizine Prevents Infusion Reactions From Paclitaxel in Breast Cancer, Other Tumors

In Clinical Studies News by Barbara Jacoby

By: Gina Mauro From: onclive.com Intravenous cetirizine showed comparable efficacy to IV diphenhydramine for the prevention of infusion reactions in patients with cancer who are undergoing treatment with an anti-CD20 antibody or paclitaxel. Intravenous (IV) cetirizine (Quzyttir) showed comparable efficacy to IV diphenhydramine for the prevention of infusion reactions (IRs) in patients with cancer who are undergoing treatment with an …

View Post

Less Diarrhea Seen When Neratinib Given in Dose-Escalated Fashion for Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Christina Bennett, MS From: cancertherapyadvisor.com Administering neratinib in a dose-escalated fashion with optional loperamide was found to reduce the incidence of severe diarrhea in patients with HER2-positive, early-stage breast cancer, according to data from the phase 2 CONTROL trial reported at the 17th St. Gallen International Breast Cancer Conference 2021. The CONTROL trial (ClinicalTrials.gov Identifier: NCT02400476) enrolled 563 patients …